Clinical trials
Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 6,204 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07068542Recruiting
New drug combo for advanced thyroid cancer
This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.
Hangzhou, ZhejiangAges 18 years+ - NCT07086768RecruitingPhase 1
BSI-082 alone or with T-DXd for advanced solid tumors
This trial tests a new drug, BSI-082, alone or with another drug (T-DXd), for people with advanced solid tumors that no longer respond to standard therapy. It aims to find the best dose and check how well it works.
San Antonio, TexasAges 18 years+ - NCT07124858Recruiting
Fruquintinib for advanced colorectal cancer
This study tracks how well fruquintinib works for people with advanced colorectal cancer that has spread. It aims to find factors that predict better outcomes, using blood and tumor samples.
Poitiers, FranceAges 18 years+ - NCT07130032RecruitingPhase 2
Immunotherapy combo for advanced lung cancer or melanoma
This trial tests a combination of immunotherapy drugs (anti-PD-1/PD-L1 antibodies) plus bevacizumab and a low-dose chemotherapy called cyclophosphamide for people with advanced lung cancer or melanoma who have already been on immunotherapy and their cancer has progressed.
Saint Petersburg, Sankt-PeterburgAges 18 years+ - NCT07134153RecruitingPhase 1/Phase 2
T-DXd injected into spinal fluid for HER2 breast cancer with brain spread
This trial tests a new way of giving the targeted drug T-DXd—directly into the fluid around your spine (intrathecal) or through a device under your scalp called an Ommaya reservoir. It's designed for people with HER2-positive breast cancer that has spread to the brain or the lining of the brain/spinal cord.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07143045Recruiting
Zorifertinib for lung cancer that has spread to the brain
This trial tracks how well zorifertinib works as a first treatment for people with a specific type of advanced lung cancer that has spread to the brain or spinal cord lining. Participants may receive zorifertinib or another standard treatment, and researchers will monitor their response over time.
Hefei, AnhuiAges 18 years+ - NCT07208773RecruitingPhase 1/Phase 2
Study of YL201 and Ivonescimab for advanced solid tumors
This trial tests a new drug combination (YL201 and Ivonescimab) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Guangzhou, GuangdongAges 18 years+ - NCT07213817RecruitingPhase 1/Phase 2
Safety and effectiveness of IPN60300 for advanced solid tumors
This trial tests a new drug called IPN60300 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT07213830RecruitingPhase 1/Phase 2
Study of IPN01203 for advanced solid tumors after immunotherapy
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
Boston, MassachusettsAges 18 years+ - NCT07219147RecruitingPhase 1
Combination treatment for advanced prostate cancer
This trial tests a combination of two treatments for advanced prostate cancer that has stopped responding to hormone therapy. One treatment is a targeted radiation therapy (177Lu-PSMA-617) and the other is an immunotherapy (sipuleucel-T) that helps your immune system fight the cancer.
Duarte, CaliforniaAges 18 years+ - NCT07220135RecruitingPhase 2
Comparing two drug combos before surgery for HER2+ breast cancer
This trial tests two different combinations of chemotherapy and targeted therapy given before surgery for HER2-positive breast cancer. The goal is to see which combination works better at shrinking the tumor.
Fairway, KansasAges 18 years+ - NCT07221149RecruitingPhase 2/Phase 3
Pumitamig vs Nivolumab for untreated stomach or esophagus cancer
This trial compares two treatments for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. One group gets pumitamig plus chemotherapy, the other gets nivolumab plus chemotherapy. The goal is to see which combination works better.
Phoenix, ArizonaAges 18 years+ - NCT07221734RecruitingPhase 3
Testing MB11 versus Opdivo for advanced melanoma
This trial compares a new drug, MB11, to the standard treatment Opdivo for people with advanced melanoma that hasn't been treated yet. The goal is to see if MB11 works just as well.
FunchalAges 18 years+ - NCT07227233RecruitingPhase 2
AI-guided retrial of CDK4/6 inhibitors for advanced breast cancer
This trial tests whether an artificial intelligence (AI) tool can help doctors decide if it is safe and effective to give you a second course of a CDK4/6 inhibitor drug (like palbociclib, ribociclib, or abemaciclib) plus hormone therapy for advanced (unresectable or metastatic) HR+/HER2- breast cancer. The goal is to only treat people whose cancer is likely to respond based on a special AI analysis of their tumor tissue.
La Jolla, CaliforniaAges 18 years+ - NCT07233499RecruitingPhase 2
Nebivolol for heart protection during breast cancer treatment
This trial tests if the drug nebivolol can protect the heart from damage caused by trastuzumab (Herceptin) in women with HER2-positive breast cancer. If effective, it may help prevent heart problems while still allowing cancer treatment.
CairoAges 18–65 - NCT07558733RecruitingPhase 1/Phase 2
New drug combinations for advanced hormone-receptor positive breast cancer
This trial tests two new drugs (sapanisertib and serabelisib) alone or together to treat advanced breast cancer that is hormone-receptor positive. These drugs target specific pathways that help cancer grow, and the trial will see if they work better than standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT07260188Recruiting
Breast cancer organoids from patients before chemo
This study collects tumor tissue from breast cancer patients before they start chemotherapy to grow miniature versions of their tumors (organoids) in the lab. The goal is to understand how each tumor responds to treatment, which may help personalize future therapies.
Pavia, PVAges 18 years+ - NCT07260305RecruitingPhase 1
Study of KGX101 alone or with Envafolimab for advanced solid tumors
This trial tests a new drug combination (KGX101 with envafolimab) for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if these drugs are safe and could help shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT07284186RecruitingPhase 1
Study of PLX-61639 for advanced SMARCA4-mutant solid tumors
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
Scottsdale, ArizonaAges 18 years+ - NCT07295457Recruiting
Exercise to prevent pain from hormone therapy in breast cancer
This trial tests whether starting a gentle exercise program early can help prevent or reduce joint and muscle pain caused by aromatase inhibitors (a common breast cancer medicine). It is for women with hormone-sensitive breast cancer who are not yet experiencing severe pain from their treatment.
LyonAges 18–75 - NCT07309770RecruitingPhase 2
Trastuzumab Rezetecan for advanced solid tumors that have stopped responding to standard treatments
This trial tests a new drug called Trastuzumab Rezetecan in people with advanced solid tumors that are HER2-positive and have not responded to standard therapies. It includes three specific groups: people with extramammary Paget's disease, rare solid tumors, or urothelial carcinoma. The goal is to see if this drug can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07312760Recruiting
Talking therapy for existential distress in advanced cancer
This trial compares a short-term psychodynamic therapy (ORPHYS) with usual care for people with advanced cancer who are struggling with existential distress, such as loss of hope, fear of death, or loneliness. It aims to see if this therapy can help improve emotional well-being.
DüsseldorfAges 18 years+ - NCT07319195RecruitingEarly Phase 1
Study of a new drug injected into tumors for breast cancer
This trial tests a drug called mitazalimab injected directly into the tumor for patients with early-stage or recurrent breast cancer who are scheduled for surgery. The goal is to see if this approach can help the immune system fight the cancer before surgery.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07327970Recruiting
AI test to predict breast cancer treatment response
This study tests whether an AI tool can predict how well breast cancer responds to chemotherapy given before surgery. Your tumor sample from a needle biopsy will be analyzed to see if the AI's prediction matches your actual treatment outcome.
IncheonAges 18 years+
Hear when a new Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 6,204 recruiting advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.